Trial Profile
A prospective, real-world, non-interventional study in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab in routine clinical practice
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PROMiS
- 30 Oct 2018 New trial record
- 12 Oct 2018 Interim results (n=171) assessing treatment satisfaction ,presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.